Get started
Author

Elisabeth Wassner-Fritsch

Observed names: E Fritsch, E. Wassner, Elisabeth Wassner, Elisabeth Wassner Fritsch, Wassner-Fritsch, E.
Institution: Roche (Switzerland)
Observed institutions: Roche (Switzerland), Medical University of Lublin, Sunnybrook Health Science Centre, Université de Lyon, Monash Medical Centre, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire Henri-Mondor, Centre Hospitalier Universitaire de Montpellier, Centre Hospitalier Universitaire de Tours, Centre Hospitalier Régional et Universitaire de Nancy, Hospices Civils de Lyon, CIC Rennes, Royal Marsden Hospital, Hôpitaux Universitaires Henri-Mondor, Hôpital Saint-Louis, Institut Paoli-Calmettes, Centre Hospitalier Universitaire de Rennes, Addenbrooke's Hospital, Centre Henri Becquerel, Cross Cancer Institute, Université de Rouen Normandie
OpenAlex ID: A5055959187
Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
2008 · Robert Marcus, Kevin Imrie, et al. · Journal of Clinical Oncology · 594
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
2016 · Laurie H Sehn, Neil Chua, et al. · The Lancet Oncology · 350
Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
2013 · Franck Andre Morschhauser, Guillaume Cartron, et al. · Journal of Clinical Oncology · 206
Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
2013 · Gilles A. Salles, Franck Morschhauser, et al. · Journal of Clinical Oncology · 153
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
2014 · Guillaume Cartron, Sophie de Guibert, et al. · Blood · 152
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
2010 · F. Morschhauser, P. Marlton, et al. · Annals of Oncology · 144
PDF
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
2013 · John Radford, Andrew Davies, et al. · Blood · 128
PDF
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
2015 · Ciara L. Freeman, Franck Morschhauser, et al. · Blood · 92
PDF
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
2023 · Shaji Kumar, Carlos R. Bachier, et al. · Journal of Clinical Oncology · 47
Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study
2016 · Bruce D. Cheson, Marek Trněný, et al. · Blood · 37
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
2019 · Christiane Pott, Laurie H. Sehn, et al. · Leukemia · 33
PDF
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
2016 · Andrew Grigg, Martin J.S. Dyer, et al. · Haematologica · 26
PDF
Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.
2007 · Franck Morschhauser, Paula Marlton, et al. · Blood · 24
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
2016 · Bruce D. Cheson, Peter C. Trask, et al. · Annals of Hematology · 22
PDF
Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma
2018 · Hearn Jay Cho, Luciano J Costa, et al. · Blood · 21
GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
2015 · Laurie Helen Sehn, Neil Sun Chua, et al. · Journal of Clinical Oncology · 20
Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),
2011 · Franck Morschhauser, Guillaume Cartron, et al. · Blood · 13
Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)
2011 · Gilles Andre Salles, Franck Morschhauser, et al. · Blood · 13
Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)
2014 · Ciara Louise Freeman, Franck Morschhauser, et al. · Blood · 11
Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study
2014 · Martin JS Dyer, Andrew P Grigg, et al. · Blood · 11
Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)
2011 · John Radford, Andrew Davies, et al. · Blood · 9
Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)
2012 · Martin JS Dyer, Andrew Grigg, et al. · Blood · 8
Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
2024 · Michel Delforge, Joshua Richter, et al. · Blood · 7
Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma
2015 · Bruce D. Cheson, Peter C Trask, et al. · Blood · 7
Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),
2011 · David Carlile, Georgina Meneses-Lorente, et al. · Blood · 6
Works count: 32
Citation count: 2,149
H-index: 16
I10-index: 20
Year
Topic
Type